Free Trial

Wedbush Issues Negative Estimate for CMPX Earnings

Compass Therapeutics logo with Medical background

Key Points

  • Wedbush has revised its Q3 2025 earnings per share estimate for Compass Therapeutics (CMPX) from ($0.13) to (0.14), and projected a full-year earnings of ($0.36) per share.
  • Multiple analysts have given Compass Therapeutics a strong "buy" rating, with target prices ranging from $9.00 to $32.00, suggesting positive market sentiment despite recent earnings adjustments.
  • Compass Therapeutics has seen a significant increase in institutional investor interest, with hedge funds owning 68.43% of the company's stock after several acquisitions in recent quarters.
  • Looking to export and analyze Compass Therapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Analysts at Wedbush decreased their Q3 2025 earnings per share (EPS) estimates for shares of Compass Therapeutics in a research report issued on Monday, August 11th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.14) per share for the quarter, down from their prior estimate of ($0.13). The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.32) EPS.

Several other analysts also recently weighed in on CMPX. Guggenheim raised their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday. HC Wainwright reissued a "buy" rating and issued a $24.00 target price on shares of Compass Therapeutics in a report on Monday, April 21st. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday. Finally, Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price target for the company in a research note on Tuesday, July 1st. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $12.89.

Check Out Our Latest Report on CMPX

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $3.17 on Wednesday. The business's 50-day moving average is $2.76 and its two-hundred day moving average is $2.50. Compass Therapeutics has a 12 month low of $1.14 and a 12 month high of $4.08. The firm has a market capitalization of $438.35 million, a PE ratio of -7.04 and a beta of 1.49.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01).

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its holdings in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Compass Therapeutics during the fourth quarter valued at about $27,000. Mariner LLC acquired a new position in Compass Therapeutics in the fourth quarter worth about $30,000. Creative Planning acquired a new position in Compass Therapeutics in the second quarter worth about $30,000. Finally, Strs Ohio acquired a new position in Compass Therapeutics in the first quarter worth about $34,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

See Also

Earnings History and Estimates for Compass Therapeutics (NASDAQ:CMPX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Compass Therapeutics Right Now?

Before you consider Compass Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.

While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines